We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Abbott Diagnostics

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.
06 Jun 2020 - 09 Jun 2020
Virtual Venue
08 Jun 2020 - 11 Jun 2020
Virtual Venue

Industry News

Image: Nova Biomedical adds PT/INR test to Allegro analyzer for POC testing (Photo courtesy of Nova Biomedical)

Nova Biomedical Adds PT/INR Test to Allegro Analyzer for POC Testing

Nova Biomedical (Waltham, MA, USA) has added PT/INR testing for its Allegro capillary blood analyzer for point-of-care (POC) testing in primary care settings. With the ability to test for clotting disorders and monitor the effectiveness of blood-thinning medications, the Allegro and its StatStrip-A companion meter provide 18 clinically important tests to help physicians make therapeutic decisions and adjustments at the POC. More...
08 Apr 2020
Illustration

Global Blood Glucose Monitoring Devices Market to Reach USD 13 Billion by 2023

 The global blood glucose monitoring devices (BGMDs) market was valued at nearly USD 8 billion in 2018 and is projected to grow at a fast-paced CAGR of approximately 11% to reach USD 13 billion by 2023, driven by the phenomenal sales growth of new revolutionary continuous glucose monitoring systems (CGMs). However, the growth of CGMs will be offset by a steady decline in the blood glucose meters (BGMs) segment due to continued extreme price competition/downward pricing pressure, lowered test-strip reimbursement, and market saturation of lower-cost meters, among other factors. More...
16 Mar 2020
Illustration

Global ELISA Kits Market to Surpass USD 418.5 Billion by 2025

 The global ELISA (Enzyme-Linked Immunosorbent Assay) Kits market is projected to grow at a CAGR of 3.8% to surpass USD 418.5 billion by the year 2025, driving a CAGR of 4% in the worldwide Research ELISA market which is expected to reach USD 143.7 billion. More...
09 Mar 2020
Illustration

Thermo Fisher Scientific to Acquire QIAGEN N.V.

 Thermo Fisher Scientific Inc. (Waltham, MA, USA) has announced that it plans to acquire QIAGEN N.V. (Venlo, Netherlands), a provider of molecular diagnostics and sample preparation technologies. Thermo Fisher's boards of directors and the managing board of QIAGEN have unanimously approved Thermo Fisher's proposal to acquire QIAGEN. More...
05 Mar 2020
Illustration

New AI System Performs as Well as Expert Pathologists in Identifying Prostate Cancer

 Researchers at the Karolinska Institutet (Stockholm, Sweden) and Tampere University (Tampere, Finland) have developed a method based on artificial intelligence (AI) for histopathological diagnosis and grading of prostate cancer. The AI-system has the potential to solve one of the bottlenecks in today's prostate cancer histopathology by providing more accurate diagnosis and better treatment decisions. A study conducted by the researchers showed that the AI-system was as good at identifying and grading prostate cancer as world-leading uro-pathologists. More...
24 Feb 2020
Illustration

Quest Diagnostics Acquires Blueprint Genetics

 Quest Diagnostics (Secaucus, NJ, USA), a provider of diagnostic information services, has acquired Blueprint Genetics (Helsinki, Finland), a specialty genetic testing company with expertise in gene variant interpretation based on next generation sequencing (NGS) and proprietary bioinformatics. Together, Quest and Blueprint Genetics will broaden access to actionable insights in genetic and rare diseases, improving patient care and pharmaceutical drug research and development. More...
30 Jan 2020
Image: BioProfile FLEX2 On-Line Autosampler (Photo courtesy of Nova Biomedical)

Nova Biomedical Launches New BioProfile FLEX2 On-Line Autosampler

 Nova Biomedical (Waltham, MA, USA) has launched the BioProfile FLEX2 On-Line Autosampler (OLS), a modular system that connects as many as 10 bioreactors to one FLEX2 analyzer for up to three weeks of walkaway, automated sampling, analysis, and feedback control of key cell culture analytes. The FLEX2 measures up to 16 tests, including pH, gases, metabolites, osmolality, cell density, and cell viability. More...
03 Jan 2020


LabMedica Industry News channel reports on mergers and takeovers, on cooperative agreements and on trends in the IVD industry worldwide.
Copyright © 2000-2020 Globetech Media. All rights reserved.